Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
7.69
-0.23 (-2.90%)
Apr 29, 2026, 2:12 PM EDT - Market open
Xilio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 137.53 | 55.29 | 44.7 | 120.39 | 198.05 | Upgrade
|
| Cash & Short-Term Investments | 137.53 | 55.29 | 44.7 | 120.39 | 198.05 | Upgrade
|
| Cash Growth | 148.74% | 23.68% | -62.87% | -39.22% | 929.49% | Upgrade
|
| Receivables | 5 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 2.5 | 4.94 | 3.42 | 4.11 | 4.46 | Upgrade
|
| Total Current Assets | 145.03 | 60.23 | 48.13 | 124.5 | 202.52 | Upgrade
|
| Property, Plant & Equipment | 7.85 | 9.06 | 11.2 | 13.06 | 13.9 | Upgrade
|
| Other Long-Term Assets | 1.81 | 1.78 | 1.6 | 1.61 | 1.64 | Upgrade
|
| Total Assets | 154.69 | 71.08 | 60.93 | 139.17 | 218.06 | Upgrade
|
| Accounts Payable | 3.17 | 2.57 | 1.05 | 3.13 | 3.14 | Upgrade
|
| Accrued Expenses | 11.74 | 9.98 | 10.5 | 10.33 | 8.75 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 3.32 | 6.67 | - | Upgrade
|
| Current Portion of Leases | 1.34 | 1.19 | 1.1 | 1 | 0.88 | Upgrade
|
| Current Unearned Revenue | 40.02 | 13.52 | - | - | - | Upgrade
|
| Total Current Liabilities | 56.27 | 27.26 | 15.96 | 21.12 | 12.78 | Upgrade
|
| Long-Term Debt | - | - | - | 3.17 | 9.63 | Upgrade
|
| Long-Term Leases | 5.61 | 6.95 | 8.14 | 9.23 | 10.23 | Upgrade
|
| Long-Term Unearned Revenue | 20.64 | 19.26 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 36.89 | - | - | - | - | Upgrade
|
| Total Liabilities | 119.41 | 53.48 | 24.1 | 33.52 | 32.63 | Upgrade
|
| Common Stock | - | - | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 454.06 | 401.35 | 362.34 | 354.75 | 346.31 | Upgrade
|
| Retained Earnings | -418.79 | -383.75 | -325.51 | -249.11 | -160.89 | Upgrade
|
| Total Common Equity | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 | Upgrade
|
| Shareholders' Equity | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 | Upgrade
|
| Total Liabilities & Equity | 154.69 | 71.08 | 60.93 | 139.17 | 218.06 | Upgrade
|
| Total Debt | 6.95 | 8.14 | 12.55 | 20.07 | 20.74 | Upgrade
|
| Net Cash (Debt) | 130.58 | 47.15 | 32.15 | 100.32 | 177.32 | Upgrade
|
| Net Cash Growth | 176.94% | 46.64% | -67.95% | -43.42% | - | Upgrade
|
| Net Cash Per Share | 28.82 | 12.34 | 16.37 | 51.27 | 442.79 | Upgrade
|
| Filing Date Shares Outstanding | 5.78 | 3.7 | 2.46 | 1.96 | 1.95 | Upgrade
|
| Total Common Shares Outstanding | 4.53 | 3.27 | 1.97 | 1.96 | 1.95 | Upgrade
|
| Working Capital | 88.75 | 32.97 | 32.17 | 103.38 | 189.74 | Upgrade
|
| Book Value Per Share | 7.79 | 5.38 | 18.68 | 53.93 | 94.89 | Upgrade
|
| Tangible Book Value | 35.27 | 17.6 | 36.83 | 105.65 | 185.43 | Upgrade
|
| Tangible Book Value Per Share | 7.79 | 5.38 | 18.68 | 53.93 | 94.89 | Upgrade
|
| Machinery | 7.06 | 6.78 | 6.68 | 6.45 | 4.67 | Upgrade
|
| Construction In Progress | 0.46 | - | - | 0.1 | 0.54 | Upgrade
|
| Leasehold Improvements | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.